{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:27:49Z","timestamp":1790699269652,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ophtha.2025.02.011","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:04:59Z","timestamp":1739905499000},"page":"859-868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Risk of Glaucoma in Patients without Diabetes Using a Glucagon-Like Peptide 1 Receptor Agonist"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1381-5618","authenticated-orcid":false,"given":"Pranav","family":"Vasu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7171-1308","authenticated-orcid":false,"given":"Emily A.","family":"Dorairaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-3202","authenticated-orcid":false,"given":"Robert N.","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syril K.","family":"Dorairaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2025.02.011_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jcjo.2012.02.003","article-title":"Epidemiology of glaucoma: what\u2019s new?","volume":"47","author":"Cook","year":"2012","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.02.011_bib2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1094-9194(01)00004-4","article-title":"Intraocular pressure and glaucoma","volume":"5","author":"Ofri","year":"2002","journal-title":"Veterinary Clin North Am Exot Anim Pract"},{"key":"10.1016\/j.ophtha.2025.02.011_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0002-9394(89)90221-3","article-title":"Intraocular pressure and glaucoma","volume":"107","author":"Sommer","year":"1989","journal-title":"Am J Ophthalmol"},{"issue":"Suppl 1","key":"10.1016\/j.ophtha.2025.02.011_bib4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0039-6257(03)00006-7","article-title":"Relationship between intraocular pressure and preservation of visual field in glaucoma","volume":"48","author":"Goldberg","year":"2003","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.02.011_bib5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.5694\/mja2.50020","article-title":"Current management of glaucoma","volume":"210","author":"Lusthaus","year":"2019","journal-title":"Med J Aust"},{"key":"10.1016\/j.ophtha.2025.02.011_bib6","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ophtha.2025.02.011_bib7","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.3390\/jcm10174021","article-title":"Is obesity a risk or protective factor for open-angle glaucoma in adults? A two-database, Asian, matched-cohort study","volume":"10","author":"Chen","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ophtha.2025.02.011_bib8","doi-asserted-by":"crossref","first-page":"e509","DOI":"10.1097\/IJG.0000000000000374","article-title":"Relationship between body mass index and intraocular pressure in men and women: a population-based study","volume":"25","author":"Cohen","year":"2016","journal-title":"J Glaucoma"},{"key":"10.1016\/j.ophtha.2025.02.011_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/IJG.0000000000000573","article-title":"Effect of head position and weight loss on intraocular pressure in obese subjects","volume":"26","author":"Lam","year":"2017","journal-title":"J Glaucoma"},{"key":"10.1016\/j.ophtha.2025.02.011_bib10","first-page":"1","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ophtha.2025.02.011_bib11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ophtha.2025.02.011_bib12","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ophtha.2025.02.011_bib13","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ophtha.2025.02.011_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ophtha.2025.02.011_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1479164112441526","article-title":"GLP-1 receptor agonists: a clinical perspective on cardiovascular effects","volume":"9","author":"Mundil","year":"2012","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.ophtha.2025.02.011_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1033479","article-title":"The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer\u2019s disease","volume":"13","author":"Du","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ophtha.2025.02.011_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: an in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front Neurosci"},{"key":"10.1016\/j.ophtha.2025.02.011_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.824054","article-title":"Glucagon-like peptide 1 receptor agonists\u2014potential game changers in the treatment of glaucoma?","volume":"16","author":"Mouhammad","year":"2022","journal-title":"Front Neurosci"},{"issue":"3","key":"10.1016\/j.ophtha.2025.02.011_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ophtha.2024.08.023","article-title":"Comparative effects of GLP-1 receptor agonists and metformin on glaucoma risk in type 2 diabetes patients","volume":"132","author":"Muayad","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.02.011_bib20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ajo.2024.08.030","article-title":"Association between glucagon-like peptide-1 receptor agonists exposure and intraocular pressure change: GLP-1 receptor agonists and intraocular pressure change","volume":"269","author":"Hallaj","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.02.011_bib21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ogla.2024.03.005","article-title":"Glucagon-like peptide 1 receptor agonists: a role in glaucoma?","volume":"7","author":"Johnson","year":"2024","journal-title":"Ophthalmol Glaucoma"},{"key":"10.1016\/j.ophtha.2025.02.011_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1156829","article-title":"Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma","volume":"17","author":"Lawrence","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.ophtha.2025.02.011_bib23","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.survophthal.2021.02.003","article-title":"Glaucoma and neuroinflammation: an overview","volume":"66","author":"Quaranta","year":"2021","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.02.011_bib24","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ophtha.2024.03.004","article-title":"Association between glucagon-like peptide-1 receptor agonists and the risk of glaucoma in individuals with type 2 diabetes","volume":"131","author":"Niazi","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.02.011_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","article-title":"Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma","volume":"107","author":"Sterling","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.02.011_bib26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/BSD.0000000000000932","article-title":"Propensity score matching: a statistical method","volume":"33","author":"Kane","year":"2020","journal-title":"Clin Spine Surg"},{"key":"10.1016\/j.ophtha.2025.02.011_bib27","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.arthro.2021.06.037","article-title":"Best practice guidelines for propensity score methods in medical research: consideration on theory, implementation, and reporting. A review","volume":"38","author":"Chen","year":"2022","journal-title":"Arthrosc J Arthrosc Relat Surg"},{"key":"10.1016\/j.ophtha.2025.02.011_bib28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/dom.13086","article-title":"Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c","volume":"20","author":"Gallwitz","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ophtha.2025.02.011_bib29","first-page":"123","article-title":"Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience","volume":"6","author":"Anichini","year":"2013","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"10.1016\/j.ophtha.2025.02.011_bib30","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jdiacomp.2016.01.013","article-title":"Gender-related different effects of a combined therapy of exenatide and metformin on overweight or obesity patients with type 2 diabetes mellitus","volume":"30","author":"Quan","year":"2016","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.ophtha.2025.02.011_bib31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jamaophthalmol.2023.0610","article-title":"Risk of new retinal vascular occlusion after mRNA COVID-19 vaccination within aggregated electronic health record data","volume":"141","author":"Dorney","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.02.011_bib32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2024.02.023","article-title":"Association of ocular manifestations of Marfan syndrome with cardiovascular complications","volume":"264","author":"Tran","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.02.011_bib33","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ophtha.2024.01.032","article-title":"Association of cutaneous keloids, hypertrophic scarring, and fibrosis with risk of postoperative proliferative vitreoretinopathy","volume":"131","author":"Mammo","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.02.011_bib34","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20f13681","article-title":"Mean difference, standardized mean difference (SMD), and their use in meta-analysis: as simple as it gets","volume":"81","author":"Andrade","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.ophtha.2025.02.011_bib35","first-page":"700","article-title":"Interpreting estimates of treatment effects: implications for managed care","volume":"33","author":"Faraone","year":"2008","journal-title":"Pharm Ther"},{"key":"10.1016\/j.ophtha.2025.02.011_bib36","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1111\/dom.13339","article-title":"Glucagon-like peptide-1 receptor expression in the human eye","volume":"20","author":"Hebsgaard","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ophtha.2025.02.011_bib37","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41433-019-0603-z","article-title":"A review of systemic medications that may modulate the risk of glaucoma","volume":"34","author":"Wu","year":"2020","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2025.02.011_bib38","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ogla.2024.04.006","article-title":"Blind spots in therapy: unveiling drug-induced angle-closure glaucoma through a national analysis","volume":"7","author":"Aftab","year":"2024","journal-title":"Ophthalmol Glaucoma"},{"key":"10.1016\/j.ophtha.2025.02.011_bib39","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/jamaophthalmol.2015.2180","article-title":"Risk of angle-closure glaucoma with bupropion and topiramate","volume":"133","author":"Symes","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.02.011_bib40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.37349\/eds.2023.00015","article-title":"The protective role of GLP-1 in neuro-ophthalmology","volume":"1","author":"Sheth","year":"2023","journal-title":"Explor Drug Sci"},{"key":"10.1016\/j.ophtha.2025.02.011_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2024.1354569","article-title":"Glaucoma: from pathogenic mechanisms to retinal glial cell response to damage","volume":"18","author":"Fern\u00e1ndez-Albarral","year":"2024","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.ophtha.2025.02.011_bib42","series-title":"StatPearls [Internet]","article-title":"Open angle glaucoma, StatPearls, 2024","author":"Mahabadi","year":"2025"},{"key":"10.1016\/j.ophtha.2025.02.011_bib43","first-page":"207","article-title":"Evidence-based pathophysiology of glaucoma","volume":"5","author":"Alexandrescu","year":"2010","journal-title":"M\u00e6dica"},{"key":"10.1016\/j.ophtha.2025.02.011_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108271","article-title":"GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension","volume":"33","author":"Sterling","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.ophtha.2025.02.011_bib45","first-page":"130","article-title":"The correlation between diabetes mellitus and neurodegenerative diseases","volume":"240","author":"Schubert","year":"2023","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"10.1016\/j.ophtha.2025.02.011_bib46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ibneur.2022.12.006","article-title":"Molecular mechanisms underlying hyperglycemia associated cognitive decline","volume":"14","author":"Gupta","year":"2022","journal-title":"IBRO Neurosci Rep"},{"key":"10.1016\/j.ophtha.2025.02.011_bib47","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.molmed.2023.09.005","article-title":"Diabetes: a tipping point in neurodegenerative diseases","volume":"29","author":"Santiago","year":"2023","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ophtha.2025.02.011_bib48","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ajo.2024.10.029","article-title":"Sodium-glucose cotransporter 2 inhibitors and glaucoma in patients with type 2 diabetes","volume":"271","author":"Eng","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.02.011_bib49","series-title":"Endotext, South Dartmouth","article-title":"Pharmacologic treatment of overweight and obesity in adults","author":"Tchang","year":"2000"},{"key":"10.1016\/j.ophtha.2025.02.011_bib51","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0168-8227(11)70011-0","article-title":"Incretin effect: GLP-1, GIP, DPP4","volume":"93","author":"Kazakos","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ophtha.2025.02.011_bib52","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ophtha.2025.02.011_bib53","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ophtha.2025.02.011_bib54","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1007\/s00125-024-06144-1","article-title":"Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials","volume":"67","author":"Karagiannis","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.ophtha.2025.02.011_bib55","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ajo.2024.10.006","article-title":"Racial disparities in microinvasive glaucoma surgery for management of primary open-angle glaucoma: a propensity matched cohort study: racial disparities in MIGS for the management of POAG","volume":"271","author":"Vasu","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.02.011_bib56","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.oret.2024.01.026","article-title":"Propensity-matched analysis of the risk of age-related macular degeneration with systemic immune-mediated inflammatory disease","volume":"8","author":"Shukla","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ophtha.2025.02.011_bib57","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaophthalmol.2023.4716","article-title":"Risk of stroke, myocardial infarction, and death after retinal artery occlusion","volume":"141","author":"Wai","year":"2023","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025001320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025001320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T15:23:15Z","timestamp":1752852195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642025001320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0161642025001320"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.02.011","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Glaucoma in Patients without Diabetes Using a Glucagon-Like Peptide 1 Receptor Agonist","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}